Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy
- 1 September 1997
- journal article
- clinical trial
- Published by Elsevier in Cancer Letters
- Vol. 118 (1) , 29-35
- https://doi.org/10.1016/s0304-3835(97)00220-6
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Cancer statistics, 1997CA: A Cancer Journal for Clinicians, 1997
- Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.Journal of Clinical Oncology, 1996
- Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: Preliminary report from an ongoing trialEuropean Journal Of Cancer, 1995
- Treatment of colorectal cancer metastases confined to the liverEuropean Journal Of Cancer, 1995
- The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agentsInternational Journal of Cancer, 1995
- p53 Status and the Efficacy of Cancer Therapy in VivoScience, 1994
- Regional chemotherapy for hepatic metastases of colorectal carcinoma (continuous intraarterialversus continuous intraarterial/intravenous therapy). Results of a controlled clinical trialCancer, 1989
- Long-term survivors of colorectal cancer with unresectable hepatic metastasesDiseases of the Colon & Rectum, 1985
- Reporting results of cancer treatmentCancer, 1981
- Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylateBiochemistry, 1974